News about "antibody-drug conjugates (ADCs"

Hikal Launches New High Potency API Laboratory at its Pune Integrated Innovation Centre

Hikal Launches New High Potency API Laboratory at its Pune Integrated Innovation Centre

Hikal has inaugurated an advanced High Potency Active Pharmaceutical Ingredient (HPAPI) Laboratory at its Integrated Innovation Centre in Pune, further strengthening its end-to-end CDMO capabilities and enhancing its ability to safely develop, test and deliver highly potent compounds for the global pharmaceutical industry.

Antibody Drug Conjugates (ADCs) | 14/10/2025 | By Dineshwori

Turbine Partners with AstraZeneca to Accelerate Antibody-Drug Conjugate Discovery

Turbine Partners with AstraZeneca to Accelerate Antibody-Drug Conjugate Discovery

Turbine, a leading company specialising in virtualising biological experiments through artificial intelligence (AI), has announced a new collaboration with AstraZeneca to enhance the discovery of antibody-drug conjugates (ADCs).

Antibody-drug Conjugates (ADCs) | 09/10/2025 | By Dineshwori 117

Lilly to Establish USD 5 Billion API Manufacturing Facility in Virginia

Lilly to Establish USD 5 Billion API Manufacturing Facility in Virginia

The new site in Virginia marks the first of four new US manufacturing sites that Lilly plans to announce this year.

Antibody-drug Conjugates (ADCs) | 17/09/2025 | By Dineshwori

Cohance's Jaggaiahpet API Plant Clears USFDA Inspection with Zero 483 Observations

Cohance's Jaggaiahpet API Plant Clears USFDA Inspection with Zero 483 Observations

The United States Food and Drug Administration (USFDA) has completed a general current Good Manufacturing Practices (cGMP) audit at Cohance Lifesciences' API manufacturing facility (API Unit1) located at Jaggaiahpet, Andhra Pradesh, with zero Form 483 observations.

Antibody Drug Conjugates (ADCs) | 12/09/2025 | By Dineshwori 210

Samsung Biologics Reports Robust Q2 FY2025 Results, Driven by Full Plant Utilisation and New Offerings

Samsung Biologics Reports Robust Q2 FY2025 Results, Driven by Full Plant Utilisation and New Offerings

Samsung Biologics has announced its financial results for the second quarter of fiscal year 2025, posting strong growth across both consolidated and standalone metrics.

Antibody-drug Conjugates (ADCs | 23/07/2025 | By Dineshwori 1105


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members